AFT Pharmaceuticals says decision imminent on dual listing in NZ, Australia

Fiona Rotherham
Fri, 02 Oct 2015

By Fiona Rotherham Oct. 2 (BusinessDesk) - AFT Pharmaceuticals, a drugs developer and reseller,  has confirmed it’s close to making a final decision on a share-market listing first mooted in May. The Australian Financial Review's Street Talk column reported today that the Kiwi firm had kicked off informal investor briefings for a dual listing on the NZX and ASX, with First NZ Capital as an adviser and a value of $200 million to $300 million. AFT founder and majority shareholder Hartley Atkinson denied the reported valuation of the company...

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

Finance FREE
Money Answers: what's the best share investing strategy in a recession?
Frances Cook | Sat, 02 Jul 2022

Spreading your money through good quality companies, then leaving it alone for a few years is the boring but most likely way to build wealth for most of us. 

On the Money
On The Money: Air NZ's feeding frenzy, Kerry Prendergast's movie date, and more
Pattrick Smellie | Sat, 02 Jul 2022

In this week's OTM: Greg Foran's preference for pies, Kerry Prendergast's future at the film commission, a blast from the past from Enable Networks, and more...

The Economist
The great Silicon Valley shake-out
The Economist | Sat, 02 Jul 2022

We look at the world’s startups and identify the safe, the uneasy and the doomed.

Digital innovation could shape the future of NZ

The digital age allows us to collaborate on some of our greatest scientific and environmental challenges

Investments to sustain the momentum of building in NZ

Classic Capital has opened its Land & Build fund to qualified wholesale and eligible investors.